Rabbit Anti-FMC63 Antibody (S-2163-77)

產(chǎn)品型號(hào)：S0B5521

更新時(shí)間：2025-06-30

廠商性質(zhì)：生產(chǎn)廠家

訪(fǎng)問(wèn)量：115

服務(wù)熱線(xiàn)

15855403091

立即咨詢(xún)

產(chǎn)品分類(lèi)

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對(duì)抗體病理/IHC抗體

查看全部產(chǎn)品

神經(jīng)纖維絲輕鏈(NfL)單抗：助力神經(jīng)損傷診斷

探索CD45在免疫治療中的潛力

HA標(biāo)簽重組兔單抗具有增強(qiáng)蛋白定位的能力

產(chǎn)品介紹

FMC63 scFv （single-chain variable fragment） is a recombinant protein derived from the variable regions （VH and VL） of the anti-CD19 monoclonal antibody FMC63, linked by a flexible peptide spacer （e.g., （Gly?Ser）?）. It specifically binds to the B-cell surface antigen CD19 with high affinity （KD ~1-10 nM） and is a key targeting component in FDA-approved CAR-T therapies, such as Kymriah?. The humanized FMC63 scFv retains potent antigen recognition while minimizing immunogenicity, making it highly effective in treating B-cell malignancies, including acute lymphoblastic leukemia （ALL） and non-Hodgkin lymphoma （NHL）. Ongoing research focuses on optimizing its affinity, stability, and functionality to enhance the safety and efficacy of CAR-T cell therapies.

上一個(gè)：S0B5522Rat Anti-Mouse CD40 Antibody (S-R456)